Influence of Coinjection of DOTA-Z09591 on Biodistribution of Anti-HER2 111In-DOTA-Z02395 at 2 Hours After Injection in BALB/C nu/nu Mice
| Organ | 111In-DOTA-Z02395 (1 μg) | 111In-DOTA-Z02395 (1 μg) + 70 μg of DOTA-Z09591 | 111In-DOTA-Z02395 (70 μg) |
| Blood | 1.5 ± 0.4 | 1.2 ± 0.1 | 1.0 ± 0.2 |
| Lung | 1.8 ± 0.3 | 2.1 ± 0.5 | 1.8 ± 0.2 |
| Liver | 1.5 ± 0.3 | 1.7 ± 0.1 | 1.2 ± 0.1 |
| Spleen | 0.7 ± 0.1 | 0.8 ± 0.2 | 0.7 ± 0.1 |
| Stomach | 0.9 ± 0.1 | 1.3 ± 0.2* | 0.9 ± 0.2 |
| Colon | 0.9 ± 0.1 | 1.4 ± 0.3* | 0.83 ± 0.06 |
| Kidney | 238 ± 32 | 271 ± 21 | 215 ± 35 |
| Muscle | 0.47 ± 0.08 | 0.49 ± 0.08 | 0.43 ± 0.06 |
| Bone | 0.65 ± 0.08 | 0.77 ± 0.09 | 0.6 ± 0.1 |
↵* Significant difference (P < 0.05) between control and coinjection groups.
Data are presented as average %ID/g and SD for 4 mice.